Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine.

Merchante N, Pérez-Camacho I, Mira JA, Rivero A, Macías J, Camacho A, Gómez-Mateos J, García-Lázaro M, Torre-Cisneros J, Pineda JA; Grupo Andaluz para el Estudio de las Hepatitis Víricas de la Sociedad Andaluza de Enfermedades Infecciosas.

Antivir Ther. 2010;15(5):753-63. doi: 10.3851/IMP1612.

PMID:
20710057
2.

Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance.

Blanco F, Barreiro P, Ryan P, Vispo E, Martín-Carbonero L, Tuma P, Labarga P, Medrano J, González-Lahoz J, Soriano V.

J Viral Hepat. 2011 Jan;18(1):11-6. doi: 10.1111/j.1365-2893.2009.01261.x.

PMID:
20088890
3.

Severe liver disease associated with prolonged exposure to antiretroviral drugs.

Maida I, Núñez M, Ríos MJ, Martín-Carbonero L, Sotgiu G, Toro C, Rivas P, Barreiro P, Mura MS, Babudieri S, Garcia-Samaniego J, González-Lahoz J, Soriano V.

J Acquir Immune Defic Syndr. 2006 Jun;42(2):177-82.

PMID:
16688096
4.

Didanosine (ddI) associates with increased liver fibrosis in adult HIV-HCV coinfected patients.

Suárez-Zarracina T, Valle-Garay E, Collazos J, Montes AH, Cárcaba V, Carton JA, Asensi V.

J Viral Hepat. 2012 Oct;19(10):685-93. doi: 10.1111/j.1365-2893.2012.01596.x. Epub 2012 Mar 15.

PMID:
22967099
5.

The value of screening HIV-infected individuals for didanosine-related liver disease?

Scourfield A, Jackson A, Waters L, Gazzard B, Nelson M.

Antivir Ther. 2011;16(6):941-2. doi: 10.3851/IMP1875. No abstract available.

PMID:
21900728
6.
7.

Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study.

Boubaker K, Flepp M, Sudre P, Furrer H, Haensel A, Hirschel B, Boggian K, Chave JP, Bernasconi E, Egger M, Opravil M, Rickenbach M, Francioli P, Telenti A.

Clin Infect Dis. 2001 Dec 1;33(11):1931-7. Epub 2001 Oct 23.

PMID:
11692306
8.

Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors.

Guaraldi G, Squillace N, Stentarelli C, Orlando G, D'Amico R, Ligabue G, Fiocchi F, Zona S, Loria P, Esposito R, Palella F.

Clin Infect Dis. 2008 Jul 15;47(2):250-7. doi: 10.1086/589294.

PMID:
18532884
9.

Low risk of pancreatitis in HIV-infected patients on hydroxyurea plus didanosine.

Barreiro P, Soriano V, Valencia E, Díaz B, González-Lahoz J.

AIDS. 2001 Dec 7;15(18):2469-70. No abstract available.

PMID:
11774839
10.

Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine.

Walker UA, Bäuerle J, Laguno M, Murillas J, Mauss S, Schmutz G, Setzer B, Miquel R, Gatell JM, Mallolas J.

Hepatology. 2004 Feb;39(2):311-7.

PMID:
14767983
11.

Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome.

Castellares C, Barreiro P, Martín-Carbonero L, Labarga P, Vispo ME, Casado R, Galindo L, García-Gascó P, García-Samaniego J, Soriano V.

J Viral Hepat. 2008 Mar;15(3):165-72. doi: 10.1111/j.1365-2893.2007.00903.x.

PMID:
18233989
12.

Severe toxicity associated with the combination of tenofovir and didanosine: case report and review.

Masiá M, Gutiérrez F, Padilla S, Ramos JM, Pascual J.

Int J STD AIDS. 2005 Sep;16(9):646-8. Review.

PMID:
16176639
13.

Prevalence, risk factors and outcome of hyperlactataemia in HIV-infected patients.

Hocqueloux L, Alberti C, Feugeas JP, Lafaurie M, Lukasiewicz E, Bagnard G, Carel O, Erlich D, Molina JM.

HIV Med. 2003 Jan;4(1):18-23.

14.

Peripheral neuropathy during stavudine-didanosine antiretroviral therapy.

Reliquet V, Mussini JM, Chennebault JM, Lafeuillade A, Raffi F.

HIV Med. 2001 Apr;2(2):92-6.

15.

HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy.

Lincoln D, Petoumenos K, Dore GJ; Australian HIV Observational Database.

HIV Med. 2003 Jul;4(3):241-9.

16.

Upper gastrointestinal bleeding may unmask didanosine-associated portal hepatopathy in HIV/HCV co-infected patients.

Vispo E, Maida I, Barreiro P, Moreno V, Soriano V.

HIV Clin Trials. 2008 Nov-Dec;9(6):440-4. doi: 10.1310/hct0906-440.

PMID:
19203910
17.

Nucleoside reverse-transcriptase inhibitor use, cirrhosis, and end-stage liver disease in HIV-infected patients.

Remtulla RA, Decker CF.

Clin Infect Dis. 2008 Nov 1;47(9):1233-4; author reply 1234. doi: 10.1086/592352. No abstract available.

PMID:
18831698
18.

Acute pancreatitis associated with different combination therapies in patients infected with human immunodeficiency virus.

Guo JJ, Jang R, Louder A, Cluxton RJ.

Pharmacotherapy. 2005 Aug;25(8):1044-54.

PMID:
16207094
19.

Distal sensory polyneuropathy in HIV-positive patients in the HAART era: an entity underestimated by clinical examination.

Skopelitis EE, Kokotis PI, Kontos AN, Panayiotakopoulos GD, Konstantinou K, Kordossis T, Karandreas N.

Int J STD AIDS. 2006 Jul;17(7):467-72.

PMID:
16820077
20.

Symptomatic hyperlactatemia in an HIV-positive patient: a case report and discussion.

Antoniou T, Weisdorf T, Gough K.

CMAJ. 2003 Jan 21;168(2):195-8.

Supplemental Content

Support Center